Aceso Therapeutics

About Aceso Therapeutics

At Aceso, we leverage our technology platform to explore new molecular pathways and develop strategic approaches aimed at redefining standards of care where existing therapies are insufficient. In the development of a new therapy for cystic fibrosis, Aceso is starting with ATC-101, its most advanced program designed to address the limitations of current treatments. Supported by robust proof-of-concept data and promising preclinical evidence, we are advancing toward IND-enabling studies, with entry into clinical trials as the next major milestone. With a science-driven roadmap and a strong intellectual property position, we are well positioned to accelerate pipeline development and deliver meaningful therapeutic advances. Our strategy also includes expanding toward additional potential drug candidates to strengthen this innovative approach to cystic fibrosis, including the planned development of a bitherapy. Founded by Thomas Tran (CEO) and the scientists behind our patented molecules, Aceso is driven by a dedicated and complementary team supported by the dynamic biotech ecosystem of Montpellier in the Occitanie region, France, where the company is located. 👉 Learn more at www.aceso-therapeutics.com or contact us at contact@aceso-therapeutics.com